Cargando…

Efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: A comprehensive systematic review

Triple-negative breast cancer (TNBC) is associated with worse prognosis, with limited treatment regiments available and higher mortality rate. Immune checkpoint inhibitors targeting programmed cell death-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) showed great potentials in treating malignanc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lazarus, Gilbert, Audrey, Jessica, Iskandar, Anthony William Brian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	PAGEPress Publications, Pavia, Italy 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886008/ https://www.ncbi.nlm.nih.gov/pubmed/31857857 http://dx.doi.org/10.4081/oncol.2019.425

Ejemplares similares

Current situation of programmed cell death protein 1/programmed cell death ligand 1 inhibitors in advanced triple-negative breast cancer
por: Liang, Yuehua, et al.
Publicado: (2022)

Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis
por: Banerjee, Debasree, et al.
Publicado: (2018)

Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism
por: Jaafar, Jaafar, et al.
Publicado: (2018)

Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
por: Yu, Wei-Bo, et al.
Publicado: (2019)

Safety and Efficacy of Programmed Cell Death 1 and Programmed Death Ligand-1 Inhibitors in the Treatment of Cancer: An Overview of Systematic Reviews
por: Ou, Shun-Long, et al.
Publicado: (2022)

Comprehensive insights into the effects and regulatory mechanisms of immune cells expressing programmed death-1/programmed death ligand 1 in solid tumors
por: Liu, Min, et al.
Publicado: (2020)

Expression patterns of programmed death-1 and programmed death-1 ligand-1 on T cells in gastric cancer
por: Kim, Ji-Hyun, et al.
Publicado: (2019)

Negative regulation by Programmed Death Ligand-1 during drug-specific priming of T-cells and the influence of Programmed Death-1 on effector T-cell function
por: Gibson, Andrew, et al.
Publicado: (2014)

Elevated Expression of Programmed Death-1 and Programmed Death Ligand-1 Negatively Regulates Immune Response against Cervical Cancer Cells
por: Chen, Zhifang, et al.
Publicado: (2016)

Inhibition of MYC suppresses programmed cell death ligand-1 expression and enhances immunotherapy in triple-negative breast cancer
por: Li, Xintong, et al.
Publicado: (2022)

Positive correlation between programmed death ligand-1 and p53 in triple-negative breast cancer
por: Zeng, Yan, et al.
Publicado: (2019)

Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients
por: Zhang, Yan, et al.
Publicado: (2011)

Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis
por: Liu, Qiang, et al.
Publicado: (2017)

Programmed Cell Death-1/Programmed Cell Death-1 Ligand as Prognostic Markers of Coronavirus Disease 2019 Severity
por: Niedźwiedzka-Rystwej, Paulina, et al.
Publicado: (2022)

Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer
por: Tung, Nadine, et al.
Publicado: (2016)

Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis
por: Chang, Katherine, et al.
Publicado: (2014)

Immunohistochemical comparison of three programmed death-ligand 1 (PD-L1) assays in triple-negative breast cancer
por: Yoshikawa, Katsuhiro, et al.
Publicado: (2021)

Effect of baricitinib in regulating programmed death 1 and ligand programmed cell death ligand 1 through JAK/STAT pathway in psoriasis
por: Deepak, H. B., et al.
Publicado: (2022)

Programmed death‐ligand 1 expression in swine chronic infections and enhancement of interleukin‐2 production via programmed death‐1/programmed death‐ligand 1 blockade
por: Ganbaatar, Otgontuya, et al.
Publicado: (2021)

Efficacy and safety of programmed cell death-1/programmed cell death ligand-1 inhibitors in advanced urothelial malignancy: A systematic review and meta-analysis
por: Pattanaik, Smita, et al.
Publicado: (2019)

Overexpression of Programmed Death-Ligand 1 Receptor mRNA as an Independent Negative Prognostic Factor for Triple Negative Breast Cancer
por: Purwanto, Ibnu, et al.
Publicado: (2020)

Fatal adverse events associated with programmed cell death protein 1 or programmed cell death-ligand 1 monotherapy in cancer
por: Zhao, Bin, et al.
Publicado: (2020)

Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1
por: Zhao, Jing, et al.
Publicado: (2020)

Regulation of the programmed cell death protein 1/programmed cell death ligand 1 axis in relapsing–remitting multiple sclerosis
por: Tsaktanis, Thanos, et al.
Publicado: (2023)

Inhibition of Programmed Death Receptor-1/Programmed Death Ligand-1 Interactions by Ginsenoside Metabolites
por: Yim, Nam-Hui, et al.
Publicado: (2020)

Expression of Programmed Death-Ligand 1 and Programmed Death-1 in Patients with Extramammary Paget's Disease
por: Goto, Hiroyuki, et al.
Publicado: (2021)

Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis
por: Zhang, Chen, et al.
Publicado: (2021)

Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma
por: Chen, Kaiyan, et al.
Publicado: (2016)

Interactions between programmed death-1 and programmed death ligand-1 promote tolerance by blocking the T cell receptor-induced stop signal
por: Fife, Brian T., et al.
Publicado: (2009)

Programed death-1/programed death-ligand 1 expression in lymph nodes of HIV infected patients: results of a pilot safety study in rhesus macaques using anti–programed death-ligand 1 (Avelumab)
por: Gill, Amanda L., et al.
Publicado: (2016)

Comparison of Programmed Cell Death Ligand 1 Status between Core Needle Biopsy and Surgical Specimens of Triple-Negative Breast Cancer
por: Choi, Hyungwook, et al.
Publicado: (2023)

Programmed Death Ligand 1; An Immunotarget for Renal Cell Carcinoma
por: Chandrasekaran, Deepika, et al.
Publicado: (2019)

Clinical significance of programmed death‐1 and programmed death‐ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma
por: Mikami, Shuji, et al.
Publicado: (2019)

Corrigendum: Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1
Publicado: (2021)

The incidence of pseudoprogressive disease associated with programmed cell death 1/programmed cell death ligand 1 inhibitors: A meta-analysis
por: Zhang, Jingyi, et al.
Publicado: (2021)

Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer
por: Liu, Xiaojun, et al.
Publicado: (2016)

Cbl-b Deficiency Mediates Resistance to Programmed Death-Ligand 1/Programmed Death-1 Regulation
por: Fujiwara, Mai, et al.
Publicado: (2017)

Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas
por: Yang, Min-Wei, et al.
Publicado: (2019)

Terphenyl-Based Small-Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein–Protein Interaction
por: Muszak, Damian, et al.
Publicado: (2021)

Survival Outcomes and Safety of Programmed Cell Death/Programmed Cell Death Ligand 1 Inhibitors for Unresectable Hepatocellular Carcinoma: Result From Phase III Trials
por: Zeng, Linyan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vtksagj61j0dihp9icbep4bmpg